Main results
A total of 1352 children were enrolled from six studies. The number of children from one study was unavailable. Data interpretation was significantly limited by the inability to extract data that specifically referred to children with M. pneumoniae. Clinical response did not differ between the children randomised to a macrolide antibiotic and the children randomised to a non-macrolide antibiotic. There were no studies comparing relevant antibiotics with placebo.
Authors' conclusions
This review found insufficient evidence to draw any conclusions about the efficacy of antibiotics for LRTI secondary to M. pneumoniae in children. The use of antibiotics for M. pneumoniae LRTI has to be individualised and balanced with possible adverse events associated with antibiotic use. There is a need for high quality, double-blinded randomised controlled trials to assess the efficacy and safety of antibiotics for LRTI secondary to M. pneumoniae in children.
P L A I N L A N G U A G E S U M M A R Y
There is insufficient evidence from trials about the benefits of antibiotic treatment for lower respiratory tract infections in children secondary to Mycoplasma pneumoniae (M. pneumoniae).
M. pneumoniae is an bacterial infection often responsible for lower respiratory tract infections (LRTI) in children. The infection can present in a number of different ways and the most common respiratory manifestations are acute bronchitis, pneumonia or exacerbation of asthma. The illness is generally self-limiting with symptoms lasting several weeks. Antibiotics are often given to children with M. pneumoniae LRTI but the authors found there were no adequate trials which show that antibiotics are effective.
B A C K G R O U N D Description of the condition
Mycoplasma pneumoniae (M. pneumoniae) is widely recognised as an important cause of community acquired lower respiratory tract infection (LRTI) in children, accounting for 14% to 34% of cases (Kogan 2003; Michelow 2004; Nelson 2002; Principi 2002) . The highest attack rates are reported to occur in 5 to 20-year-olds and the infection is usually self-limiting with symptoms lasting several weeks (Nelson 2002; Rudolph 2003) . More recently M. pneumoniae has been identified as an important cause of LRTI in children less than five years of age (Principi 2001) . Pulmonary manifestations are typically tracheobronchitis or pneumonia but can be complicated by pleural effusion, lung abscess, pneumothorax, bronchiectasis and respiratory distress syndrome (Principi 2002) . M. pneumoniae is also implicated in wheezing episodes in both asthmatic and non-asthmatic individuals (Phelan 1994; Principi 2001) . Extrapulmonary manifestations may include erythema multiforme, myocarditis, encephalitis, Guillain-Barre Syndrome, transverse myelitis and haemolytic anaemia (Nelson 2002; Waites 2003) . Radiographic findings are quite variable and nondiagnostic (Principi 2001). In some cases there can be significant radiological changes in the absence of clinical signs on auscultation of the chest (so-called 'walking pneumonia') (Rudolph 2003).
Description of the intervention
Antibiotics are frequently used to treat LRTI and empiric antibiotic therapy is often chosen to cover both bacteria and atypical organisms (Kogan 2003) . A review of several major textbooks offers conflicting advice for management of M. pneumoniae LRTI. The chapter on M. pneumoniae in a paediatric respiratory textbook (Phelan 1994) mentions that there is little evidence of beneficial effect from antibiotic therapy. This is in contrast to the recommendations in a major general paediatric textbook (Rudolph 2003) and paediatric infectious disease textbook (Katz 1998) which states that erythromycin is the treatment of choice.
Why it is important to do this review
The conclusion that antibiotics are effective in M. pneumoniae chest infections seems to have been drawn from trials of antibiotic therapy for community acquired or atypical pneumonia, where M. pneumoniae was identified as a causative organism in a subgroup of cases. In these studies, macrolide antibiotics, to which M. pneumoniae is susceptible, have been compared to non-macrolide antibiotics. However, it is not always possible to draw meaningful conclusions from the results, as the numbers of individuals with M. pneumoniae are small in most trials (Block 1995; Kogan 2003; Wubbel 1999) . Identification of M. pneumoniae infection as the causative infectious agent may, however, pose difficulties. Serological tests are the most common method used to diagnose M. pneumoniae infections, but can lead to difficulties with interpretation (Principi 2001). Measurement of immunoglobulin M (IgM) is used to diagnose acute infection, but the accuracy of the test depends on the method used. Not all methods are specific for IgM and an elevated IgM may persist for months after the acute infection (Murray 2003) . Immuno-fluorescent antibody (IFA) assay is more sensitive and specific than the complement fixation (CF) test (Murray 2003; Principi 2001) . Identification of M. pneumoniae in nasopharyngeal secretions by culture or polymerase chain reaction (PCR) may also cause difficulties with interpretation as this organism can persist for variable periods following the acute infection (Murray 2003) . The 'gold standard' for diagnosis of M. pneumoniae infection is a four-fold increase in total antibody titre as measured in paired sera (Katz 1998; Murray 2003) .
O B J E C T I V E S
To determine whether antibiotics are effective in the treatment of childhood LRTI secondary to M. pneumoniae infections acquired in the community.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing antibiotics from the macrolide, tetracycline or quinolone class versus placebo, or antibiotics from any other class.
Types of participants
All trials that included children under 18 years of age with community acquired LRTI secondary to M. pneumoniae. Diagnosis of M. pneumoniae infection was via either a four-fold rise in total antibody titre from paired sera or total antibody titre ≥ 1:512 on a single specimen. Other methods of diagnosis such as culture or PCR of M. pneumoniae in nasopharyngeal secretions or demonstration of elevated IgM on a single specimen (IgM titre ≥ 1:10) were included, and analysed separately as a subgroup Exclusion criteria: (a) children with underlying chronic cardiorespiratory illnesses such as cystic fibrosis, bronchiectasis, immunodeficiency, chronic neonatal lung disease and symptomatic congenital heart disease; (b) children with non-community acquired LRTI.
Types of interventions
All randomised controlled trial (RCT) comparisons of antimicrobials from the macrolide, tetracycline or quinolone class, versus placebo or other antibiotics in the management of LRTI. Two separate treatment regimes were evaluated: (a) any antibiotic versus placebo; and (b) antibiotics from the macrolide, tetracycline or quinolone class versus placebo, or antibiotics from any other class. Trials that included the use of other medications or interventions in addition to antibiotic therapy were included if all participants had equal access to such medications or interventions.
Types of outcome measures
Attempts were made to obtain data on at least the following outcome measures:
Primary outcomes
• proportions of participants who were not improved at follow up. (Failure to improve will be measured according to the hierarchy listed below 'secondary outcomes'.)
Secondary outcomes
• mean difference in symptoms and signs (mean improvement in clinical state);
• proportions requiring hospitalisation;
• proportions experiencing pulmonary complications (empyema, pleural effusion, air leak);
• proportions experiencing non-pulmonary complications;
• proportions experiencing adverse effects (for example nausea, diarrhoea, abdominal pain, rash);
• proportions experiencing complications (for example requirement for medication change).
The proportions of participants who failed to improve on treatment and the mean clinical improvement were determined using the following hierarchy of assessment measures. All outcomes were reported but where two or more assessment measures are reported in the same study and conflicting results are obtained, the outcome measure that was listed first in the hierarchy was used. 
Searching other resources
We checked all references for reports of trials.
Data collection and analysis

Selection of studies
Retrieval of studies: From the title, abstract or descriptions, we independently reviewed literature searches to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text using specific criteria, we independently selected trials for inclusion. We measured agreement using the kappa statistic and resolved disagreement by consensus.
Data extraction and management
We independently extracted data and resolved disagreement by consensus. Trials that satisfied the inclusion criteria were reviewed and the following information recorded: study setting; year of study; source of funding; patient recruitment details (including number of eligible children); inclusion and exclusion criteria; randomisation and allocation concealment method; numbers of participants randomised; blinding (masking) of participants, care providers and outcome assessors; intervention (type of anti-microbials, dose, duration); control (type, dose, duration); co-interventions; numbers of patients not followed up; reasons for withdrawals from study protocol (clinical, side-effects, refusal and other); details on side-effects of therapy; and whether intention-totreat analyses were possible. Data were extracted on the outcomes described previously. We requested further information from the study authors where required.
Assessment of risk of bias in included studies
We independently assessed the quality of studies included in the review. Four components of quality were assessed: 1. Allocation concealment. Trials will be scored as: Grade A: Adequate concealment; Grade B: Unclear; Grade C: Clearly inadequate concealment (Grade A = high quality).
2. Blinding. Trials will be scored as: Grade A: Participant and care provider and outcome assessor blinded; Grade B: Outcome assessor blinded; Grade C: Unclear; Grade D: No blinding of outcome assessor (Grade A, B = high quality). 3. Reporting of participants by allocation group. Trials will be scored as: Grade A: The progress of all randomised children in each group described; Grade B: Unclear or no mention of withdrawals or dropouts; Grade C: The progress of all randomised children in each group clearly not described (Grade A = high quality). 4. Follow up. Trials will be scored as: Grade A: Outcomes measured in more than 90% (where withdrawals due to complications and side-effects are categorised as treatment failures); Grade B: Outcomes measured in 80 to 90%; Grade C: Unclear; Grade D: Outcomes measured in less than 80% (Grade A = high quality). While only the allocation concealment quality is displayed in the meta-analysis figures, all assessments were included in the table 'Characteristics of included studies'. Inter-author reliability for the identification of high quality studies for each component was measured by the kappa statistic. Each study was assessed using a one to five scale described by Jadad (Jadad 1996) and summarised as follows:
• Was the study described as randomised? (1 = yes; 0 = no) • Was the study described as double blind? (1 = yes; 0 = no)
• Was there a description of withdrawals and dropouts? (1= yes; 0 = no)
• Was the method of randomisation clearly described and appropriate? (1= yes; 0 = no)
• Was the method of double blinding well described and appropriate? (1= yes; 0 = no)
Unit of analysis issues
In the protocol it was planned to calculate relative and absolute risk reductions using an intention-to-treat analysis for the dichotomous outcome variables of each individual study. However, data were unavailable. In the protocol it was planned to include the results from studies that met the inclusion criteria and report any of the outcomes of interest in the subsequent meta-analysis. It was planned to calculate the summary weighted risk ratio and 95% confidence interval (CI) (fixed effect model) using the inverse of the variance of each study result for weighting (Cochrane statistical package, Review Manager 4.2). It was planned to calculate the numberneeded -to treat using the summary odds ratio and the average control event rate described in the relevant studies. It was stated in the protocol that the cough indicies were assumed to be normally distributed continuous variables so the mean difference in outcomes could be estimated (weighted mean difference). In studies that reported outcomes using different measurement scales, the standardised mean difference would be estimated. However, data were unavailable. In the protocol it was planned to describe any heterogeneity between the study results and, depending upon the number of trials included in the review, a funnel plot was planned to look for publication bias. However, data were unavailable and no studies were included in a meta-analysis. In the protocol it was intended to perform an a priori subgroup analysis for:
1. children aged seven years and older; 2. intervention type (class of antibiotics); 3. diagnostic criteria used for identification of M. pneumoniae. However, data were unavailable. In the protocol a sensitivity analyses was planned to assess the impact of the potentially important factors on overall outcomes:
1. study quality; 2. study size; 3. variation in the inclusion criteria; 4. differences in the medications used and duration of treatment in the intervention and comparison groups; 5. differences in outcome measures; 6. analysis by 'treatment received' rather than 'intention-to treat'. However, data were unavailable.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
Results of the search
The initial search identified 91 potentially relevant titles. After reviewing the abstracts, 17 papers in full text were obtained for consideration of inclusion into the review. Ten papers were excluded and details are provided in the table 'Characteristics of excluded studies'. The main reasons for exclusion were the non-randomised nature of the study (Jensen 1967; Sakata 2001; Vasilos 1995) or use of inadequate placebo or comparator (Block 1995; Chien 1993; Jensen 1967; Manfredi 1992; Nogeova 1997; Ronchetti 1994; Schonwald 1990; Yin 2002) . Three of the excluded studies were non-English -Japanese (Sakata 2001), Russian (Vasilos 1995) and Chinese (Yin 2002) . Seven studies were included and details are provided in the table 'Characteristics of included studies'. Three of the included studies were non-English -German (Ruhrmann 1982) and Spanish (Gomez Campdera 1996; Saez-Llorens 1998).
Included studies
Participants
The studies involved children diagnosed with LRTI ranging in age from 1 month to 16 years. In all except two studies (Gomez Campdera 1996; Soderstrom 1991) children had pneumonia supported with abnormal chest x-ray and apart from the study by Ruhrmann 1982 the children were described as having community acquired pneumonia. The study by Gomez Campdera 1996 did not define pneumonia and the study by Soderstrom 1991 included patients with acute bronchitis. The number of children with M. pneumoniae was not stated in three studies (Gomez Campdera 1996; Ruhrmann 1982; Saez-Llorens 1998) . In one study (Wubbel 1999) there were 12 children with M. pneumoniae infections and 6 were in the subgroup randomised to either azithromycin or amoxycillin-clavulanate, but the number assigned to each therapy was not available. In two other studies the number of children with M. pneumoniae infections in each intervention group was provided -in the study by Harris 1998 there were 30 children who had M. pneumoniae infections randomised to either azithromycin or amoxycillin-clavulanate (21 in azithromycin group and 9 in amoxycillin-clavulanate group), and there were eight children in the study by Kogan 2003 (five in azithromycin group and three in amoxycillin-clavulanate group). In the study by Soderstrom 1991 there were only seven patients with lower respiratory tract infections (bronchitis) and one case of M. pneumoniae, but the age of the patient with M. pneumoniae was not provided.
Interventions
Studies included in this review involved patients with LRTI randomised to either a macrolide antibiotic or another antibiotic, usually a different macrolide or non-macrolide antibiotic. In two studies (Ruhrmann 1982; Soderstrom 1991) the entire study population was randomised to either a macrolide or non-macrolide antibiotic. Ruhrmann 1982 included children with pneumonia who received either erythromycin 70 to 80 mg/kg/day or amoxycillin 60 to 70 mg/kg/day. The duration of therapy was not stated. The study by Soderstrom 1991 had a subgroup of patients (number of children not stated) with acute bronchitis who received either erythromycin 500 mg twice daily for seven days or phenoxymethylpenicillin 800 mg twice daily for seven days. Four studies (Gomez Campdera 1996; Harris 1998; Saez-Llorens 1998; Wubbel 1999) randomised a subgroup of children under five years of age to azithromycin or amoxycillin-clavulanate. The dose of amoxycillin-clavulanate was 40 mg/kd/day in three divided doses for 10 days in all studies. The dose of azithromycin was 10 mg/kg once daily for three days in one study (Gomez Campdera 1996) and 10 mg/kg on day 1 followed by 5 mg/kg once daily for day 2 to 5 in three studies (Harris 1998; Saez-Llorens 1998; Wubbel 1999) . In the study by Kogan 2003 the intervention for the subgroup with classic pneumonia was either azithromycin 10 mg/kg once daily for three days or amoxycillin 75 mg/kg/day in three divided doses for seven days. Outcomes Clinical response was the main outcome but was not defined in three studies (Gomez Campdera 1996; Ruhrmann 1982; Soderstrom 1991) . In three studies clinical cure was defined as complete resolution of symptoms and signs by day 15 to 19 (Harris 1998), day 10 to 25 (Saez-Llorens 1998) and day 10 to 37 (Wubbel 1999). In the study by Kogan 2003 the clinical response was defined as the proportion of children without fever on day 3. Radiological outcome was recorded in three studies (Gomez Campdera 1996; Harris 1998; Kogan 2003) but was not defined in the study by Gomez Campdera 1996. Bacteriological outcome was recorded in two studies (Harris 1998; Saez-Llorens 1998) but was not defined in the study by Saez-Llorens 1998. Adverse events were recorded by four studies (Gomez Campdera 1996; Harris 1998; Saez-Llorens 1998; Wubbel 1999) and were only defined in the study by Harris 1998. Attempts were made to obtain individual patient data from three studies (Harris 1998; Kogan 2003; Wubbel 1999) where the number of children with M. pneumoniae was identified, but no reply was received at the time this review was completed.
Risk of bias in included studies
Jadad scores ranged from 1 to 3, with one study scoring 1 (Gomez Campdera 1996), five studies scoring 2 (Harris 1998; Kogan 2003; Ruhrmann 1982; Saez-Llorens 1998; Wubbel 1999) and one study scoring 3 (Soderstrom 1991). Agreement between the two authors for quality of studies varied with weighted kappa score of 0.18 for Jadad score and 0.49 for quality assessment. A discussion between reviewers on how to interpret the Jadad scoring system did not take place beforehand and this, along with the small numbers involved, was reflected in the low kappa score. The main discrepancy in quality assessment arose with interpretation of allocation concealment and reporting of participants by allocated group. Disagreement in both instances was resolved by consensus. Randomisation All studies were described as randomised and the method of randomisation was clearly described and appropriate in two studies (Ruhrmann 1982; Saez-Llorens 1998) where a random number list was used. The method of randomisation was unclear in one study (Wubbel 1999) where the method used was described as a list of randomised therapy assignments. In the study by Soderstrom 1991 the method used was sequential patient numbers and this was thought to be inadequate. Three studies (Gomez Campdera 1996; Harris 1998; Kogan 2003) did not describe the method of randomisation.
Allocation
Concealment of allocation was unclear in all except two studies (Saez-Llorens 1998; Wubbel 1999) , where therapy was assigned by pharmacy.
Blinding
There was no blinding in four studies (Gomez Campdera 1996; Ruhrmann 1982; Saez-Llorens 1998; Wubbel 1999) . In the remaining three studies the blinding involved only the participant (Harris 1998), clinician (Kogan 2003) or radiologist (Soderstrom 1991).
Effects of interventions
There were 1352 children enrolled from six studies. The number of children from one study (Soderstrom 1991) was unavailable. Data interpretation was significantly limited by the inability to extract data that specifically referred to children with M. pneumoniae. There were no studies of children randomised to any antibiotic versus placebo. The included studies comprised a subgroup of children who were randomised to a macrolide versus non-macrolide antibiotic. The total number of children in this subgroup was not known as the numbers were only available in four studies (Harris 1998; Kogan 2003; Ruhrmann 1982; Wubbel 1999) . The number of children with LRTI secondary to M. pneumoniae in this subgroup was only available in two studies (Harris 1998; Kogan 2003) and the lack of individual patient data did not allow for inclusion of results in a meta-analysis. There was a total of 26 in azithromycin group and 12 in amoxycillin-clavulanate group. In the study by Gomez Campdera 1996 the rate of clinical cure was 95.12% in the azithromycin group and 90.41% in the amoxycillin-clavulanate group. Radiological improvement was noted in 90.6% of the azithromycin group. Adverse events were recorded in 11.25% of the azithromycin group and 17.14% in the amoxycillin-clavulanate group. Harris 1998 reported no difference in the rate of clinical cure at day 15 to 19 (67.2% versus 66.7%) and four to six weeks (85.1% versus 85.4%) of children randomised to azithromycin or amoxycillin-clavulanate. M. pneumoniae was identified in 16% (30 of 188 children under five years of age). Eradication of M. pneumoniae occurred in three out of three in the azithromycin group and in none out of one in the amoxycillinclavulanate group. Adverse events in those children under five years of age were 12.1% in the azithromycin group and 42.3% in the amoxycillin-clavulanate group. One patient in each group discontinued treatment because of adverse events. In the study by Kogan 2003 which compared azithromycin to amoxicillin in children with classical pneumonia (8 children of 47 had M. pneumoniae), xray resolution was significantly better in those treated with azithromycin (81% versus 60.9% at day 7) but there was no difference in clinical symptoms or signs between groups. In those with atypical pneumonia (23 children of 59 had M. pneumoniae) there was no significant difference between children treated with azithromycin or erythromycin (Kogan 2003) . Ruhrmann 1982 reported clinical cure after 3.79 days in erythromycin group and 3.96 days in amoxycillin group. Saez-Llorens 1998 reported a similar clinical response (99% versus 98%) in children under five years who were randomised to azithromycin or amoxycillin-clavulanate. Eradication of M. pneumoniae occurred in 23 out of 24 in the azithromycin group. Adverse events were reported in 11% on azithromycin, 30% on amoxycillin-clavulanate and 27% on erythromycin. Soderstrom 1991 did not report the clinical response in the subgroup of patients with bronchitis. In the study by Wubbel 1999, where 7% (12 of 168 children) had M. pneumoniae, no difference was found in children randomised to azithromycin or amoxicillinclavulanate. Adverse events were reported in 14% on azithromycin, 67% on amoxycillin-clavulanate and 25% on erythromycin. Eleven patients did not complete the prescribed therapy.
D I S C U S S I O N
Summary of main results
This review failed to find any randomised controlled trials which specifically looked at the effectiveness of antibiotics for LRTI secondary to M. pneumoniae. There were no studies of antibiotics versus placebo. In the subgroup of children with LRTI secondary to M. pneumoniae the intervention was a macrolide antibiotic versus a non-macrolide antibiotic, usually amoxycillin-clavulanate. This subgroup identified only 38 children with M. pneumoniae infection and there were insufficient data to analyse the efficacy of macrolide antibiotics in this group. Adverse events were common, reported in 11% to 67% of children. The majority of adverse events related to the gastrointestinal tract (diarrhoea, vomiting, abdominal pain, nausea, anorexia) and where reported, were more common in younger children (under five years of age).
Quality of the evidence
There were significant difficulties in interpretation of data from the included studies. Firstly, although all studies (except Soderstrom 1991) enrolled children with LRTI, only a proportion had M. pneumoniae infection. It was not possible to obtain information on the sub-group with M. pneumoniae. Secondly, the dose and type of antibiotics differed among studies. Thirdly, application of diagnostic criteria (serology versus PCR) varied and these are not necessarily interchangeable. Fourthly, the inclusion criteria differed (various types of LRTI manifestation) between studies. Furthermore the outcomes measured were variable and in some papers, clinical cure was undefined. Despite the commonality of M. pneumoniae LRTI in children (up to 40% of CAP reported by Waites 2003), there is surprisingly no RCT that has specifically evaluated the efficacy of antibiotics for the treatment of childhood LRTI secondary to M. pneumoniae infections acquired in the community. This is reflected in conflicting advice given in paediatric textbooks (Phelan 1994; Rudolph 2003) and this systematic review has highlighted the need for such studies.
A U T H O R S ' C O N C L U S I O N S Implications for practice
This review found insufficient evidence to draw any conclusions about the efficacy of antibiotics for LRTI secondary to M. pneumoniae in children. The use of antibiotics for M. pneumoniae LRTI has to be individualised depending on the clinical context (for example setting, clinical history and signs, presence of immunodeficiency etc) and balanced with possible adverse events associated with antibiotic use.
Implications for research
M. pneumoniae infection is relatively common and its clinical manifestations range from being asymptomatic to death from complications of M. pneumoniae infection. As respiratory symptoms are the most common symptoms, there is a need for high quality, double-blinded randomised controlled trials to assess the efficacy and safety of antibiotics for LRTI secondary to M. pneumoniae in children. Studies should consider the various clinical and microbiological diagnostic criteria of M. pneumoniae infection and utilise clear outcome criteria. Community studies using PCR for rapid early diagnosis would be valuable to evaluate the efficacy of antibiotics for M. pneumoniae for respiratory and non respiratory manifestations as well as for prevention of complications and microbiological clearance of M. pneumoniae.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Gomez Campdera 1996
Methods
Patients were recruited from emergency department with a diagnosis of pneumonia for the periods 
Risk of bias
Item
Authors' judgement Description
Allocation concealment? Unclear B -Unclear
Harris 1998
Methods Patients were recruited from 23 centres with a diagnosis of community acquired pneumonia from 31 January 1994 to 31 May 1995. Inclusion criteria were children with clinically suspected pneumonia based on a radiological finding and the presence of tachyapnoea. In addition patients had at least one of the following: fever or history of fever within 24 hours, cough, WCC >= 12000/mm, or chest findings suggestive of pneumonia. Exclusion criteria were hypersensitivity to macrolides, penicillin or beta-lactam antibiotics, pregnancy or lactation, parenteral therapy required because of severe or multilobar pneumonia, treatment with any other systemic antibiotics within enrolment, evidence of underlying haematological, renal, hepatic or cardiovascular disease, chronic steroid use or concomitant treatment with theophylline, carbamazine, ergotamine, digitalis glycosides, terfenadine, loratadine or astemizole. Study was a multicentre, parallel group in which participants were randomised 2:1 to azithromycin or either amoxycillinclavulanate if under 5 years and erythromycin if over 5 years. The method of randomisation was not described. Participants were blinded to therapy but there was no mention of blinding of clinicians or outcome assessors. There was a description of withdrawals or dropouts. There was an assessment of compliance by comparing medication bottle weights at beginning and end of study. Patients were evaluated at four clinic visits: baseline; study days 2 to 5; study days 15-19; and 4-6 weeks post therapy. Laboratory tests were obtained at baseline and on Study days 15-19. Chest x-rays were obtained at baseline and 4-6 weeks post-therapy. Evidence of infection with M. pneumoniae was determined by enzyme-linked immunosorbent assay and defined as either single positive serum IgM (>= 1:10) or 4-fold increase in IgG titre. Clinical response at study days 15 to 19 was classified as: cure, complete resolution of signs and symptoms of pneumonia; improvement, incomplete resolution of signs and symptoms of pneumonia; failure, persistence (or progression) of signs and symptoms of pneumonia after 3 days of therapy or development of new clinical findings consistent with active infection or persistence (or progression) of radiological findings obtained when clinically indicated. Clinical response 4 to 6 weeks post-therapy was classified as follows: cure; complete resolution of signs and symptoms of pneumonia and improvement or resolution of radiographic findings; failure; persistence (or progression) of signs and symptoms of pneumonia after 3 days of therapy or development of new clinical findings consistent with active infection or persistence (or progression) of radiological findings. Bacteriological response was classified as follows: eradication (presumed or proven), elimination of the original organism from the same site during or after completion of therapy and includes cases where repeat specimens were nor obtained and patients considered a clinical cure or improved; persistence, failure to eradicate the organism and includes cases where specimens were not obtainable at the time alternative therapy was instituted and the patient was considered a clinical failure. Adverse events were monitered throughout the study by reported symptoms, physical examinations and laboratory tests. Events were rated by severity (mild, moderate or severe at the discretion of the investigator), organ system and relation to study drug Assessment of Quality 1. Allocation concealment: Grade B 2. Blinding: Grade C 3. Reporting of participants by allocation group: Grade A 4. Follow up: Grade B Jadad Score: 2 Participants 456 children aged 6 months to 15 years with CAP were enrolled. 36 patients (25 in azithromycin group and 11 in comparator group) were excluded for methodologic reasons leaving 420 patients (285 in azithromycin and 135 in comparator group) available for analysis. Six children discontinued treatment because of adverse events. Males = 236. The number of children with M. pneumoniae in the group randomised to macrolide versus non-macrolide (i.e. children < 5 years) was 30 with 21 in azithromycin group and 9 in amoxycillin-clavanulate group
D A T A A N D A N A L Y S E S
This review has no analyses.
W H A T ' S N E W
Last assessed as up-to-date: 20 May 2005.
Date Event Description
22 July 2008 Amended Converted to new review format. 
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D E C L A R A T I O N S O F I N T E R E S T
None known.
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